{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000137","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.719620+00:00","generated_at":"2026-06-10T13:31:59.240647+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BeiGene regains full global rights to tislelizumab after terminating Novartis license agreement","bullets":["On September 17, 2023, BeiGene Switzerland and Novartis mutually terminated the Collaboration and License Agreement for tislelizumab, effective immediately.","BeiGene regains full global rights to develop, manufacture, and commercialize tislelizumab with no royalty payments due to Novartis.","Novartis may continue ongoing clinical trials and conduct future combination trials with tislelizumab subject to BeiGene's approval.","Novartis will provide transition services including manufacturing, regulatory, safety, and clinical support for tislelizumab.","The termination covers licensed territories: US, Canada, Mexico, EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000137","json":"https://secwatch.observer/filing/0001651308-23-000137.json","markdown":"https://secwatch.observer/filing/0001651308-23-000137.md","text":"https://secwatch.observer/filing/0001651308-23-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/0001651308-23-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/bgne-20230917.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T13:31:59.240647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"963bbcfc5d6f0fc22637f36ddd70eb5e804f4942","claim":"BeOne Medicines Ltd. terminated Mutual Termination and Release Agreement with Novartis Pharma AG (effective 2023-09-17).","evidence_excerpt":"On September 17, 2023, BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Agreement”) to mutually terminate the License Agreement, effective immediately.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/0001651308-23-000137-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Effective","value":"2023-09-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}